Physician profile
Luis M Gely
NPI 1861427650
$89,351.78
in general payments reported to CMS, 2019-2025
18 companies · $2,291 in 2025
The $2,291 reported for 2025 was more than what 85% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $42K · 2020: $20K · 2021: $5,329 · 2022: $10K · 2023: $6,509 · 2024: $1,965 · 2025: $2,291.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $8,977 · Food and Beverage: $1,789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $8,976.50 |
| Food and Beverage | $1,788.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34,373.22 | 2019-2023 | Eliquis |
| Pfizer Pharmaceuticals LLC | $16,694.17 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14,873.00 | 2019-2023 | Jardiance |
| Janssen Pharmaceuticals, INC | $7,276.83 | 2019-2023 | Xarelto |
| Eli Lilly Export S.A. Puerto Rico Branch | $4,525.00 | 2019 | |
| Lilly USA, LLC | $4,507.15 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $3,147.51 | 2024-2025 | Pneumovax 23, Winrevair |
| Pfizer INC. | $2,040.31 | 2019-2025 | |
| Medtronic, INC. | $718.52 | 2019-2025 | Symplicity G3, Micra, Na |
| Boston Scientific Corporation | $381.44 | 2019-2025 | Watchman Flx, Farapulse, Lux-Dx Insertable Cardiac Monitor |
| Actelion Pharmaceuticals US, INC. | $212.21 | 2022-2024 | Opsumit, Uptravi |
| Astrazeneca Pharmaceuticals LP | $145.88 | 2019-2024 | Brilinta, Farxiga |
| Bridgebio Pharma, INC. | $125.00 | 2025 | Attruby |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $109.88 | 2019-2024 | Lifevest |
| Pbg Puerto Rico LLC | $80.23 | 2021-2023 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $66.50 | 2025 | |
| Amgen INC. | $59.14 | 2019-2021 | |
| Abbott Laboratories | $15.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Luis Gely listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.